Argan Inc Announces 2025 Stockholder Meeting Results

By Ahmed Jameison • Wednesday, June 18 06:08 • Permanent Link

Argan, Inc. recently announced the results of its 2025 Annual Meeting of Stockholders, revealing several key outcomes.

First, the election of nine directors to the Board of Directors saw significant support, with all nominees receiving substantial "FOR" votes. Lisa L. Alexander garnered 9,767,417 votes, Cynthia A. Flanders received 9,242,585, and Peter W. Getsinger secured 9,784,858 votes. The lowest "FOR" votes went to William F. Leimkuhler with 9,419,442 and James W. Quinn with 9,436,542.

In terms of executive compensation, the non-binding advisory approval (say-on-pay vote) received 9,011,132 "FOR" votes, while 810,416 were "Against," and 31,732 abstained.

The non-binding advisory vote on the frequency of stockholder votes on executive compensation (say-on-frequency vote) resulted in 9,382,351 votes in favor of an annual vote, 4,909 for a biennial vote, and 455,128 for a triennial vote, with 10,892 abstentions.

Additionally, the amendment to the Company’s Certificate of Incorporation to limit the personal liability of certain officers and directors saw 8,554,758 "FOR" votes, 1,271,849 "Against," and 26,673 abstentions.

Finally, the ratification of Grant Thornton LLP as the Company’s independent registered public accountants for the fiscal year ending January 31, 2026, received overwhelming support, with 11,521,610 "FOR" votes and 76,957 "Against," while 7,039 abstained. As a result of these announcements, the company's shares have moved 0.19% on the market, and are now trading at a price of $218.59. Check out the company's full 8-K submission here.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.